ADVERTISEMENT

Medical News

Capecitabine chemotherapy beneficial for patients with nasopharyngeal carcinoma

Heather Mason   |   18 October 2022

Promising results for patients with locally advanced nasopharyngeal carcinoma (LA-NPC) following capecitabine treatment as second-line therapy.

The open-label randomised clinical trial included 90 Chinese patients who received capecitabine adjuvant therapy 1000 mg/m 2 twice daily for 14 days every three weeks for eight cycles. A further 90 patients were observed following their primary...

          

November Challenge

Ends in 10h
left
right

Topic Challenges

left
right